Vatalanib (Not yet branded)

Targeted Therapy

Experimental

Not submitted to EMA

Not available Oral 2 Clinical Trials

VEGFR-1 VEGFR-2 VEGFR-3 PDGFR c-Kit

Description

Vatalanib is an oral multi-targeted tyrosine kinase inhibitor that was developed for the treatment of metastatic colorectal cancer in combination with standard chemotherapy regimens. This small molecule inhibitor was designed to block multiple receptor tyrosine kinases involved in tumor angiogenesis and growth. Clinical trials evaluated vatalanib in combination with FOLFOX (oxaliplatin, 5-fluorouracil, and leucovorin) chemotherapy for patients with metastatic colorectal cancer, including both treatment-naive and previously treated patients.

Mechanism of Action

Vatalanib functions by inhibiting multiple receptor tyrosine kinases, primarily targeting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, and VEGFR-3), platelet-derived growth factor receptor (PDGFR), and c-Kit. By blocking these signaling pathways, vatalanib disrupts tumor angiogenesis and may also have direct anti-tumor effects. The inhibition of VEGF receptor signaling is particularly important in colorectal cancer, as this pathway promotes the formation of new blood vessels that tumors require for growth and metastasis.

Molecular Targets

VEGFR-1 VEGFR-2 VEGFR-3 PDGFR c-Kit

Side Effects

Diarrhea Hypertension Fatigue Nausea Hand-foot syndrome Decreased appetite Proteinuria Bleeding events

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT00056459 Phase 3

Completed

Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Metastatic Colorectal Cancer.

United States, Australia, Belgium, Brazil, Canada, Czechia, France, Germany, Hun

NCT00056446 Phase 3

Archived

Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal Cancer

United States, Australia, Austria, Belgium, Brazil, Canada, France, Germany, Hon

Quick Info

Brand Name	Not yet branded
Category	Targeted Therapy
Status	Experimental
EMA Status	Not submitted to EMA
Spain Access	Not available
Administration	Oral
Clinical Trials	2

View Clinical Trials Back to Drug Glossary

Related Medications

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.